Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) EBIT: 2019-2025

Historic EBIT for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to -$69.9 million.

  • CureVac N.V's EBIT rose 11.84% to -$69.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.3 million, marking a year-over-year increase of 121.87%. This contributed to the annual value of $189.9 million for FY2024, which is 164.36% up from last year.
  • CureVac N.V's EBIT amounted to -$69.9 million in Q2 2025, which was down 21.41% from -$57.6 million recorded in Q1 2025.
  • Over the past 5 years, CureVac N.V's EBIT peaked at $591.5 million during Q3 2024, and registered a low of -$395.7 million during Q4 2024.
  • For the 3-year period, CureVac N.V's EBIT averaged around -$38.7 million, with its median value being -$74.0 million (2023).
  • In the last 5 years, CureVac N.V's EBIT tumbled by 392,922.67% in 2021 and then spiked by 1,105.60% in 2024.
  • Over the past 5 years, CureVac N.V's EBIT (Quarterly) stood at -$6.3 million in 2021, then tumbled by 1,866.40% to -$124.0 million in 2022, then rose by 23.61% to -$94.7 million in 2023, then crashed by 317.89% to -$395.7 million in 2024, then rose by 11.84% to -$69.9 million in 2025.
  • Its EBIT stands at -$69.9 million for Q2 2025, versus -$57.6 million for Q1 2025 and -$395.7 million for Q4 2024.